AI Was Once A Specialist Topic. What Will Your Clients Ask About Next?

Longevity biotech may be the next expertise gap. Get a free briefing on how to evaluate the science, evidence and economics before hype or fear replaces analysis.

What the recent Insilico aging-clock headline actually showed
Why too risky and binary are not complete analyses
Seven questions for separating evidence, financing risk and potential mispricing

Free. No stock picks. No investment promises.

Educational research only. Not investment or medical advice.